Recent FDA committee vote could speed multiple myeloma drug approval
A U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma.
May 22, 2024
0
2